Crispr Therapeutics AG (CRSP) Receives a Buy from Wells Fargo

By Jason Carr

Wells Fargo analyst Jim Birchenough maintained a Buy rating on Crispr Therapeutics AG (CRSPResearch Report) yesterday. The company’s shares closed last Monday at $72.37, close to its 52-week high of $74.00.

According to, Birchenough is a 5-star analyst with an average return of 21.4% and a 51.0% success rate. Birchenough covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Ionis Pharmaceuticals, and Akcea Therapeutics.

Crispr Therapeutics AG has an analyst consensus of Moderate Buy, with a price target consensus of $75.83, implying a 6.1% upside from current levels. In a report issued on November 25, Oppenheimer also maintained a Buy rating on the stock with a $80.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $74.00 and a one-year low of $22.22. Currently, Crispr Therapeutics AG has an average volume of 871.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, and Shaun Patrick Foy in 2014 and is headquartered in Zug, Switzerland.